Furmecil is soon going to be available in the Indian market is in the form of capsules of two strengths
BDR Pharmaceuticals has launched FURMECIL (popularly known as S-1 which is a combination of three drugs – Tegafur, Gimeracil & Oteracil). FURMECIL is an oral drug, indicated in adults for the treatment of advanced gastric cancer, which has demonstrated high effectiveness with a favourable safety profile.
Furmecil is soon going to be available in the Indian market is in the form of capsules in two strengths (Tegafur 15 mg + Gimeracil 4.35 mg + Oteracil 11.80 mg & Tegafur 20 mg + Gimeracil 5.80 mg + Oteracil 15.80 mg)
Commenting on the launch, Raheel Shah, Director Business Development on behalf of BDR Pharmaceuticals Int’l , Mumbai said, “Our vision is to bring globally available and highly effective but expensive medicines to the Indian patients making them accessible at affordable prices, BDR Pharma, takes the lead to bring cost-effective treatment for Gastric cancer in India as part of its latest pharmaceutical innovation. Our focused launch of such first time newly advanced molecule in the treatment of various cancer indications is testimony to our solid commitment to providing access to affordable medicines for Indian cancer patients with high-quality standards without compromising patient’s safety.”
